Cancer Medicines Market to reach $124.9bn in 2019, predicts a new visiongain study

LONDON - Oct. 8, 2015 - PRLog -- Cancer medicinesmarket to reach $124.9bn in 2019, predicts a new visiongain study

A new report by visiongain forecasts the world market for cancer-treating drugs will reach $124.9 billion in 2019. That revenue prediction and others appear in World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025,published in July 2015. Visiongain is a business information publisher and consultancy in London, UK.

That new analysis predicts the global cancer-treating drugs market will expand at a CAGR of 7% from 2014 to 2019, driven by the immunotherapy and targeted therapy submarkets. Overall world revenue expansion will also be stimulated by rising incidence of cancer in developing countries, widening access to healthcare, shifts towards personalised medicine and drug development that gives more options and better treatments.

Sandra Wenas, a pharmaceutical industry analyst in visiongain, said: “The anti-cancer drugs market will continue to grow over the next ten years. Despite generic erosion due to patent expiry on some leading anti-cancer drugs, that market will gain successful new products, including orphan drugs for rare cancers. Many R&D studies focus on immunotherapy and targeted therapy, in line with the increasing interest in personalised medicine. Both submarkets will grow significantly in revenues from 2015 to 2025 and remain mainstays of the anti-cancer drugs market.

“A topic that is often debated in the anti-cancer drugs industry is the justification of high treatment cost. Pharmaceutical companies, medical practitioners, patient advocates, payers, governments and other stakeholders are still to find a pricing and payment model that fits the wishes of all parties. That debate will remain important from 2015, affecting the industry and market for cancer therapies.”

Visiongain’s new investigation shows revenue forecasts to 2025 at overall world market, submarket, product and national level. First it forecasts revenues of four submarkets:

·         Immunotherapy

·         Chemotherapy

·         Targeted treatments

·         Hormone-based therapy.

That study then forecasts revenues from 2015 to 2025 for the top 25 anti-cancer drugs on the market in 2015.Those products include Avastin, Herceptin, Rituxan, Gleevec/Glivec and Revlimid. In addition, the report forecasts revenues of 15 emerging drugs approved in 2014 and 2015.

The work also profiles eight top companies and discusses more than 70 products in research and development. That analysis explains activities and prospects of organisations such as Roche, Novartis, Celgene, Eli Lilly and AstraZeneca. It includes interviews with two authorities on that market.

In addition, the study explains trends and shows revenue forecasts to 2025 for 11 national markets for cancer therapies:

·         United States (US)

·         Japan

·         Germany, France, United Kingdom (UK), Italy and Spain (EU5 group)

·         Brazil, Russia, India and China (BRIC countries).

Visiongain predicts that China, Brazil and India will expand fast in anti-cancer drug revenues from 2014 to 2025, with those sales rising by CAGR values surpassing 10%. Worldwide that market will prove itself as one of the strongest parts of the pharmaceuticals industry. Existing and new cancer treatments will benefit patients, healthcare providers and companies.

World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025adds to visiongain’s range of analytical reports on industries and markets in healthcare. Those studies cover pharmaceuticals, technologies, medical devices, diagnostic tests and outsourced services.